Patients receiving the tafasitamab combination achieved a median PFS of 22.4 months, compared with 13.9 months for patients receiving placebo with lenalidomide and rituximab. This represents a 57% ...
Cancer survivors may experience anxiety over minor illnesses, fearing recurrence despite being in remission. The "positivity trap" can make survivors feel invalidated, as constant reassurance may ...
Dr. Ian Flinn explains in an interview with CURE how Lunsumio VELO (mosunetuzumab) works and its impact on patients with ...
"Histological transformation of FL to DLBCL was a low‐incidence event associated with distinct clinical features and inferior survivals . . . By population‐based analysis and external validation, ...
Follicular lymphoma is an indolent malignancy with a generally favorable prognosis, with survival often measured in decades. Yet up to 20% of patients develop early progression after starting ...
DIAMOND BAR, Calif., Aug. 13, 2025 /PRNewswire/ -- CIT Therapeutics, Inc. (CIT), a biotechnology company focused on developing next-generation small molecule therapies targeting SUMOylation for cancer ...
Breyanzi provided sustained clinical benefit with a median duration of response not reached. Don’t miss this list of 3 high-yield stocks—including one delivering over 10%—built for income in today’s ...
Important facts to keep in mind. re than 30 million Americans have a thyroid disorder and an excess of 60,000 Americans are affected by thyroid cancer annually. — -- intro: You probably don't ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results